# Efficacy of Dapagliflozin in Diabetes Associated Peripheral Neuropathy

> **NCT05162690** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Post Graduate Institute of Medical Education and Research, Chandigarh** · enrollment: 40 (estimated)

## Conditions studied

- Diabetic Peripheral Neuropathy

## Interventions

- **DRUG:** Dapagliflozin 10 milligram
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05162690
- **Lead sponsor:** Post Graduate Institute of Medical Education and Research, Chandigarh
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-05-01
- **Primary completion:** 2023-12-31
- **Final completion:** 2023-12-31
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2022-06-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05162690

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05162690, "Efficacy of Dapagliflozin in Diabetes Associated Peripheral Neuropathy". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05162690. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*